

## Asthma Indicators for LHIN 11: Champlain

Indicator	Asthma Indicators for LHIN 11: Champlain																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) <sup>†</sup>	49.56	50.44	48.79	47.86	51.15	51.43	52.54	51.13	52.84	54.32	54.15	60.74	63.51	64.33	62.73	60.83	60.15	58.72	59.67	60.88	61.29	62.87	62.78
2. PFT used for monitoring (% of prevalent asthma) <sup>†</sup>	14.60	12.98	12.76	12.35	11.43	11.47	11.09	10.63	9.88	9.59	9.53	9.52	8.83	9.25	9.61	9.61	8.82	8.10	7.80	7.87	7.77	7.60	7.65
3. ≥1 ICS prescription (% of prevalent asthma) <sup>‡</sup>	56.26	55.15	54.83	53.76	52.91	52.13	51.48	49.67	49.62	49.59	48.12	48.05	47.79	47.65	47.85	48.67	48.18	47.73	46.59	46.73	44.98	42.59	40.69
4. ≥1 β2-agonist prescription (% of prevalent asthma) <sup>‡</sup>	57.81	55.80	54.63	54.89	52.79	51.51	49.06	46.46	45.31	44.46	43.05	42.68	40.62	39.65	39.67	39.76	37.96	37.19	33.22	23.76	23.74	21.29	20.31
5. ≥1 asthma ED visit (% of prevalent asthma)	4.60	4.24	3.65	3.44	3.52	3.17	3.08	2.56	2.38	2.19	2.25	1.99	1.58	1.57	1.53	1.45	1.26	1.30	1.13	1.23	1.05	1.02	1.00
6. ≥1 asthma physician office visit (% of prevalent asthma)	38.13	34.76	31.77	31.24	28.33	26.52	23.56	22.47	20.75	19.20	18.79	18.70	16.67	16.01	16.12	15.20	13.82	13.34	12.94	12.93	12.05	11.60	11.51
7. β2-agonist use (% of prevalent asthma) <sup>‡</sup>																							
0	42.19	44.20	45.37	45.11	47.21	48.49	50.94	53.54	54.69	55.54	56.95	57.32	59.38	60.35	60.33	60.24	62.04	62.81	66.78	76.24	76.26	78.71	79.69
1-2	18.88	19.33	18.48	19.72	19.20	19.71	18.83	18.28	18.92	19.71	19.08	19.82	19.24	18.74	18.96	19.41	18.63	18.64	16.84	12.05	12.18	10.67	9.96
≥3	38.93	36.47	36.15	35.17	33.59	31.80	30.23	28.19	26.39	24.75	23.97	22.86	21.38	20.91	20.71	20.35	19.33	18.55	16.38	11.71	11.56	10.62	10.35

\*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

<sup>†</sup>PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

<sup>‡</sup>Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

### Technical notes:

<sup>a</sup>OHIP data was up to December 2019 when the tables were created.

<sup>b</sup>For asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

<sup>c</sup>Individuals with missing LHIN, rurality, or without OHIP coverage were excluded.

<sup>d</sup>Asthma incidence of the year were excluded from this table, except for indicator 1.

<sup>e</sup>Index date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

### Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date<sup>a-c</sup>
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date<sup>a,c-e</sup>
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date<sup>c-e</sup>
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date<sup>c-e</sup>
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date<sup>c-e</sup>
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date<sup>c-e</sup>
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above<sup>c,d</sup>

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.